<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805232</url>
  </required_header>
  <id_info>
    <org_study_id>artesunate and malaria</org_study_id>
    <nct_id>NCT01805232</nct_id>
  </id_info>
  <brief_title>Intravenous Artesunate and Malaria</brief_title>
  <acronym>IVAS</acronym>
  <official_title>Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kassala, Sudan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kassala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sudan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Khartoum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous artesunate is egual to quinine in the treatment of severe malaria
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous artesunate is egual to quinine in the treatment of severe malaria in the form of
      fever clearance time and parasite clearance time
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clearance of the parasite and fever</measure>
    <time_frame>3 days</time_frame>
    <description>To compare the parasite clearance time and fever clearance time between the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous artesunate 80 mg/kg initially then after 8 hours then daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>quinine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>quinine infusion 80 mg/kg every 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artesunate</intervention_name>
    <description>intravenous artesunate 80 mg/kg initially then after 8 hours then daily</description>
    <arm_group_label>artesunate</arm_group_label>
    <arm_group_label>quinine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinine</intervention_name>
    <description>quinine infusion 80 mg/kg every 8 hours till the patient can take orally</description>
    <arm_group_label>artesunate</arm_group_label>
    <arm_group_label>quinine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        severe P.falciparum malaria-

        Exclusion Criteria:

        mixed infection Pregnant women -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kassala</name>
      <address>
        <city>Kassala</city>
        <zip>249</zip>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abzinab A Ali, MD</last_name>
      <phone>+249911259199</phone>
      <phone_ext>122</phone_ext>
      <email>ishagadamm@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Tajeldien A Abdulla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <reference>
    <citation>Eltahir HG, Omer AA, Mohamed AA, Adam I. Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2010 Oct;104(10):684-6. doi: 10.1016/j.trstmh.2010.05.009. Epub 2010 Jun 17.</citation>
    <PMID>20850004</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Khartoum</investigator_affiliation>
    <investigator_full_name>Ishag Adam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>severe</keyword>
  <keyword>Falciaparum</keyword>
  <keyword>Malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

